Renal Pelvis Cancer
14
2
4
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (14)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
A Genotype-Phenotype Urothelial Cancer Registry
Radical Radiotherapy Versus Radical Surgery for UTUC
Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria
Urine DNA Methylation Detection for Hematuria Evaluation
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Cancer in Patients With Gabapentin (GPRD)
Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer